Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropeginterferon alfa-2b - PharmaEssentia

Drug Profile

Ropeginterferon alfa-2b - PharmaEssentia

Alternative Names: AOP-2014; Besremi; P-1101; Peg-IFN-alpha-2b; PEG-P-IFN-alpha-2b; Pegylated proline interferon-alfa-2b; Ropeg

Latest Information Update: 05 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmaEssentia Corporation
  • Developer AOP Orphan Pharmaceuticals AG; Institute of Liver and Biliary Sciences; Mayo Clinic; National Cancer Institute (USA); PharmaEssentia Corporation
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols; Small molecules
  • Mechanism of Action Interferon alpha 2b stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Polycythaemia vera
  • Phase III Essential thrombocythaemia; Hepatitis B; Hepatitis C
  • Phase II Chronic myeloid leukaemia; Myelofibrosis
  • Preclinical Cancer

Most Recent Events

  • 02 Dec 2019 PharmaEssentia Japan plans a phase II trial for Polycythemia vera in Japan in December 2019 (NCT04182100)
  • 21 Aug 2019 Phase-III clinical trials in Hepatitis B in China, South Korea, Vietnam, Thailand (SC), prior to August 2019 (PharmaEssentia pipeline, August 2019)
  • 21 Aug 2019 Phase-III clinical trials in Hepatitis C in Taiwan, South Korea, China (SC), prior to August 2019 (PharmaEssentia pipeline, August 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top